This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Less skeletal muscle is associated with increased mortality risk in patients with cardiac amyloidosis — especially the transthyretin type — highlighting muscle mass as a key prognostic factor.
Medscape Medical News